AZ Respiratory webinar ‘Anti-inflammatory reliever therapy – from evidence to clinical practice’

AstraZeneca are delighted to invite you to attend the upcoming meeting, ‘Anti-inflammatory reliever therapy – from evidence to clinical practice’.

You may be aware of the recent licensing approval for Symbicort reliever therapy which is likely to significantly change how patients with asthma are managed and will be incorporated into the Wessex Asthma Network guidelines. Professor Richard Beasley led the pivotal trials underpinning the use of Symbicort reliever therapy and will be discussing the evidence behind this treatment change and how this can be implemented clinically.

To register to attend in-person or virtually please click:

• https://qr.short.az/Reliever

This educational meeting by AstraZeneca will contain promotional content.